CRI Trials - Cancer Research Institute

Science-based clinical research

An Essential Step Toward a Cure

Clinical trials are an essential step toward regulatory approval of new cancer treatments. Patients who volunteer for these studies not only gain access to cutting-edge immunotherapies and receive the best quality cancer care but also help to further the greater cause of finding immunotherapy-based cures for all cancer patients.

Driven by Data

CRI clinical trials are driven by the latest scientific data as well as the greatest opportunities for saving more lives, including finding more effective ways to help people with especially hard-to-treat, “orphan,” or rare and ultra-rare cancers.

CRI trials are built upon solid scientific rationale and are designed not only to help patients now but also to yield new insights that will benefit more patients with other cancers now and in the future.

Sharing Data to Stimulate New Ideas

Discoveries from this clinical work are shared across the entire international community of cancer immunologists. This sharing of data stimulates new ideas that lead to more progress. CRI convenes these leaders in immuno-oncology and facilitates dialogue and further knowledge sharing, fostering collaborations that otherwise would not happen.

The CRI Trials program is housed in the CRI Anna-Maria Kellen Clinical Accelerator, a first-of-its-kind collaborative network of tumor immunologists, treating physician-scientists, and pharmaceutical and biotech partners. The Accelerator sources the brightest and best thinking from the global CRI Network to advance immunotherapy in hard-to-treat and under-studied cancers.

Potential for a Universal Cure

Immunotherapy’s universal potential to effectively treat all cancers means studies done on one cancer type yield insights into the treatment of other cancers. CRI’s landscape analysis reveals where there are gaps in clinical research and where CRI and its partners can make the greatest impact.

CRI Trials include the following programs:

Anna-Maria Kellen Clinical Accelerator

Centralized and investigator-initiated clinical studies that rely on CRI’s global think tank of clinical immuno-oncology experts to design and carry out early-stage clinical trials of novel immunotherapy combinations.

LEARN ABOUT THE ACCELERATOR

Stylized graphic of a bar and line graph superimposed on one another

Immuno-Oncology Landscape

Regular analysis of immuno-oncology drug trials around the world, highlighting trends in the IO clinical drug development pipeline and guiding CRI and other clinical research programs seeking to make an impact both in increasing immunotherapy’s effectiveness overall as well as in underserved patient populations.

SEE OUR TRIAL ANALYSIS

Immuno-Oncology Clinical Trial Finder Service

Matches patients to immunotherapy clinical trials with the help of trial navigators, who work with patients and caregivers to find the most appropriate studies.

The William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, regarded as the Nobel of cancer immunotherapy research, has been given to some of the world’s most gifted scientists. Their work has deepened our understanding of the immune system’s response to cancer and other diseases and advanced the development of effective immunotherapies.

The Frederick W. Alt Award for New Discoveries in Immunology is presented annually to a former Cancer Research Institute postdoctoral fellow in recognition of outstanding success in advancing scientific research that has made a major impact in the field of immunology.

FIND A CLINICAL TRIAL